Product analysis
Mega D-3 5000 IU & MK-7 180 mcg supplies nutrients that support normal bone and mineral balance. Its identified MK-7 and low serving cost support its appeal.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality70
The identified MK-7 is a favorable vitamin K form. Vitamin D’s source is named, but there is not enough information for a comparative quality judgment.
Ingredient Transparency100
Both nutrient amounts and their forms or sources are disclosed. That makes the combination easier to compare with other D and K supplements.
Value For Money70
The serving cost is low for the MK-7 supplied. Vitamin D’s value cannot be judged separately with confidence.
Customer Satisfaction97
Customer ratings are very positive. The large number of ratings offers a broad view of sentiment, without proving effectiveness.
Product Focus80
The clearest purpose is nutritional support for bone and mineral balance. Findings for artery flexibility are limited to particular groups, and an extra benefit from combining D and K is not established.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.17
- Also available
Mega D-3 5000 IU & MK-7 180 mcg$26.60- Customer rating
- 4.9 · 93,077 ratings
Goals
Impact
Highest effect
Vitamin D · 125 mcgVitamin K · 180 mcg
Vitamin D and vitamin K supply nutrients relevant to bone and mineral balance, with their value depending on low intake rather than added benefit above adequate intake. The supplied information does not establish extra benefit from combining them or from the MenaQ7 form. Calcium is claimed in the stored label text, but its presence and amount remain unconfirmed and it was not counted.
How this product is rated for Everyday Health
Ingredient fit94
Vitamin D and K support the nutritional focus; calcium remains unresolved.
Goal fit
Vitamin D and K support the nutritional focus; calcium remains unresolved.
Dose adequacy
The known vitamin D and K amounts reach the saved comparison ranges.
Pathways60
Bone and mineral balance is the strongest area. Coverage is concentrated in bone and mineral balance.
Depth
Bone and mineral balance is the strongest area.
Breadth
Coverage is concentrated in bone and mineral balance.
Evidence82
Vitamin D anchors the nutritional evidence. Nutritional roles do not establish added benefit above adequate intake.
Evidence strength
Vitamin D anchors the nutritional evidence.
Studied preparation
The two counted nutrients have accepted preparations.
Formulation logic100
Vitamin D and K can contribute independently. No configured ingredient conflict was found.
Partner coverage
Vitamin D and K can contribute independently.
Conflicts
No configured ingredient conflict was found.
Effective doses
Both known nutrient amounts contribute meaningfully.
Impact
Highest effect
Vitamin K · 180 mcgVitamin D · 125 mcg
Vitamin D supports calcium absorption and normal mineralization when intake or status is low. The identified MK-7 provides a connection to limited bone-density findings in postmenopausal women at 180 mcg daily, although results are mixed and fracture prevention is unestablished. The high vitamin D serving does not prove greater benefit. Calcium presence and amount remain unresolved despite the supplied label claim, limiting the partner finding.
How this product is rated for Bone Health
Ingredient fit94
Vitamin K is a key ingredient in the saved bone-related findings. The amount criteria are met.
Goal fit
Vitamin K gives the formula a focused bone-related connection, although the product has other linked uses.
Dose adequacy
The credited amounts meet the saved comparison criteria; higher intake does not establish better bone outcomes.
Pathways80
Coverage is strongest for calcium absorption and regulation. The breadth finding includes calcium absorption and regulation, activation of bone proteins.
Depth
The strongest saved coverage concerns calcium absorption and regulation; coverage does not establish a change in bone density or fracture risk.
Breadth
The routes meeting the breadth criterion are calcium absorption and regulation, activation of bone proteins. Other bone functions receive less or no coverage.
Evidence98
MK-7 has limited, mixed bone-density evidence in postmenopausal women; fracture prevention and broader population benefits are unestablished.
Evidence strength
MK-7 has limited, mixed bone-density evidence in postmenopausal women; fracture prevention and broader population benefits are unestablished.
Studied preparation
The credited preparations meet the saved criteria, while the supplied nutritional, population and outcome limitations still apply.
Formulation logic92
The saved findings identify an unmet partner requirement for vitamin d; its contribution is retained with that limitation. No evaluated ingredient conflict was identified.
Partner coverage
The saved findings identify an unmet partner requirement for vitamin d; its contribution is retained with that limitation.
Conflicts
No ingredient conflict was identified by the evaluated rules.
Effective doses
All credited ingredients meet the saved minimum amount criterion; this is not a proven effective dose or fracture-prevention threshold.
Impact
High effect
Vitamin K · 180 mcgVitamin D · 125 mcg
Vitamin K as the declared MenaQ7 MK-7 preparation has limited support for arterial-stiffness changes in healthy postmenopausal women. The 180 mcg serving receives full saved amount recognition, without establishing cardiovascular-event prevention. Vitamin D’s 125 mcg serving also receives saved amount credit, but supplementation has not demonstrated routine cardiovascular prevention, and no additional benefit from combining D and K is established.
How this product is rated for Heart Health
Ingredient fit94
MK-7 provides the main relevant connection. The counted amounts receive full recognition in the saved comparison.
Goal fit
MK-7 gives this product a focused connection to heart-related functions, though it is also linked to other goals.
Dose adequacy
The counted ingredients receive full amount recognition in the saved comparison; this does not establish a proven effective dose.
Pathways60
The saved findings concentrate on the MK-7 arterial-stiffness category. Other pathways do not reach the breadth threshold.
Depth
The strongest saved contribution is in the MK-7 arterial-stiffness category.
Breadth
Only the MK-7 arterial-stiffness category reaches the saved breadth threshold; the findings remain concentrated in that area.
Evidence77
MK-7 leads the evidence comparison, with limited arterial-stiffness findings in healthy postmenopausal women. The saved preparation finding recognizes the counted preparations.
Evidence strength
MK-7 leads the evidence comparison, with limited arterial-stiffness findings in healthy postmenopausal women.
Studied preparation
The counted ingredients qualify as studied preparations in the saved findings; this does not establish product-specific trial results or superior delivery.
Formulation logic100
Partner requirements are satisfied and the counted ingredients meet the saved minimum amount comparison. No configured ingredient conflict was matched in the supplied facts.
Partner coverage
The counted ingredients have no unmet partner requirement in the saved findings; this does not imply extra benefit from combining them.
Conflicts
No configured ingredient conflict was matched in the supplied facts.
Effective doses
All counted ingredients meet the saved minimum amount comparison; this threshold is not a clinically proven effective dose.
Impact
Highest effect
Vitamin K · 180 mcgVitamin D · 125 mcg
MenaQ7 vitamin K2 has narrow findings for selected arterial-stiffness measures in postmenopausal women after three years of use. The 180 mcg serving matches the daily study amount. Vitamin D can support muscle function when deficiency is corrected, but the larger amount here does not imply greater benefit in replete adults or an added benefit from combining D3 with K2.
How this product is rated for Longevity
Ingredient fit94
The formula's focus and amounts produce a relatively close fit with the saved ingredient references. The overall roles remain bounded by the specific evidence for this product.
Goal fit
The relevant ingredients are concentrated on this goal, although links to other uses affect its focus.
Dose adequacy
The recognized amounts closely match the saved amount references; this does not establish additional benefit above nutritional adequacy.
Pathways60
The saved findings are strongest for arterial calcification control, with limited breadth across the other aging-related processes.
Depth
The strongest saved finding concerns arterial calcification control; this describes ingredient roles rather than a demonstrated slowing of aging.
Breadth
Only one pathway reaches the saved coverage threshold, leaving the formula's recognized reach narrow.
Evidence83
Vitamin D drives the leading saved evidence finding. The ingredient-specific limitations above still restrict which practical benefits can be expected.
Evidence strength
Vitamin D supplies the leading saved evidence finding, but its specific population and outcome limitations still apply.
Studied preparation
The saved findings recognize preparation matches for the qualifying ingredients; this does not extend their evidence to broader aging outcomes.
Formulation logic100
The saved formulation findings identify no matched conflicts and no missing required partners. Amount limitations are retained in the individual findings.
Partner coverage
The recognized ingredients either work independently or have their required partner; no extra combination benefit is established.
Conflicts
No matched ingredient conflict was recorded in the supplied calculation.
Effective doses
All recognized ingredients meet the saved amount threshold, which is a calculation reference rather than proof of anti-aging efficacy.
Impact
High effect
Vitamin K · 180 mcgVitamin D · 125 mcg
Vitamin K as MK-7 has limited evidence for improving selected measures of arterial stiffness in postmenopausal women. This serving supplies 180 mcg, matching the daily amount in the supplied three-year trial. Those marker changes do not establish prevention of cardiovascular events, and vitamin D does not establish an added cardiovascular effect or D3/K2 synergy.
How this product is rated for Cardiovascular Support
Ingredient fit94
MK-7 provides the main cardiovascular connection, while also having broader uses.
Goal fit
MK-7 provides the main cardiovascular connection, while also having broader uses.
Dose adequacy
The declared amounts receive full recognition in the saved findings; this does not establish a clinically optimal serving.
Pathways60
The saved findings concentrate on the artery-related route; the supplied clinical evidence is limited to arterial-stiffness measures.
Depth
The saved findings concentrate on the artery-related route; the supplied clinical evidence is limited to arterial-stiffness measures.
Breadth
Only one route has substantial coverage in the saved findings; broader cardiovascular effects are not established.
Evidence69
MK-7 has limited evidence for arterial-stiffness markers in postmenopausal women.
Evidence strength
MK-7 has limited evidence for arterial-stiffness markers in postmenopausal women.
Studied preparation
The explicit MK-7 identity matches the preparation considered in the supplied vascular studies.
Formulation logic100
The counted ingredients can contribute alone or have the partner required by the saved findings.
Partner coverage
The counted ingredients can contribute alone or have the partner required by the saved findings.
Conflicts
No evaluated ingredient conflict was found in the supplied facts.
Effective doses
All counted ingredients clear the saved contribution threshold, without establishing a treatment dose.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin D-3 (Lanolin) | 125 mcg | |
Vitamin K-2 (Menaquinone-7) | 180 mcg |
Vitamin K (Menaquinone-7) · 180 mcg OverallScore93
The label lists 180 mcg of vitamin K per serving, at a low cost per serving. The label names MK-7. MK-7 is named, but its trans form is not specified.
How this ingredient is rated
Active Ingredient Quality & Bioavailability82
The label names MK-7. MK-7 is named, but its trans form is not specified.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
The label names MK-7.
MK-7 Isomer Disclosure
MK-7 is named, but its trans form is not specified.
Dose, Safety & Label Transparency100
The vitamin K amount and form are stated. The label states 180 mcg of MK-7 per serving.
Vitamin K2 (MK-7) Dosage Efficacy
The label states 180 mcg of MK-7 per serving.
Form and Subtype Transparency
The vitamin K amount and form are stated.
Value100
The cost per serving is low.
Price per Effective MK-7 Serving
Each serving has a low cost.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Pregnancy vitamin D supplementation and offspring bone mineral density in childhood follow-up of a randomized controlled trial.
- Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
- Efficacy of vitamin D fortified foods on bone mineral density and serum bone biomarkers: A systematic review and meta-analysis of interventional studies.
- Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial.
- Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Comparative Efficacy of Nutraceuticals on Endothelial Function: A Systematic Review and Network Meta-Analysis.
- A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD.
- Randomized, placebo-controlled, double-blind clinical trial on the contributions of vitamin D in the control of cardiovascular risk factors, depressive symptoms and suicide risk.
- Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial.
- Paricalcitol and endothelial function in chronic kidney disease trial.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.